The latest anti-diabetic medication sodium-glucose co-transporter inhibitor along with the lowering of blood glucose has a cardioprotective and reno-protective effect, it has the ability to reduce the development of heart failure and decrease hospitalization in heart failure subjects with and without diabetes. This study was conducted to evaluate the effect of sodium-glucose co-transporter inhibitor dapagliflozin alone and in combination with eplerenone on the aldosterone hormone in the treatment of rats with experimentally induced heart failure
dapagliflozin, eplerenone, heart failure, aldosterone, neurohormonal change.
How to Cite This Article
Jawhar, Skala Mamand and Mustafa, Zana Ahmed
"The The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure,"
Polytechnic Journal: Vol. 12:
2, Article 7.